Q2 Revenue Surges 199% on Zusduri Sales, Net Loss Significantly Narrows; Secures Long-Term Mitomycin Supply
URGN has more than doubled off its 52-week low of $15.86.
Summary
UroGen Pharma announced Q2 2026 results with a 199% revenue increase driven by Zusduri sales and a significantly reduced net loss, alongside securing a 10-year mitomycin supply agreement.
Key Events · Earnings and Guidance · URGN
-
Strong Revenue Growth Driven by Zusduri
Q2 2026 revenue surged 199% to $72.5 million from $24.2 million in Q2 2025, primarily due to $50.4 million in sales from Zusduri, which launched in late Q2 2025. Year-to-date revenue increased 177% to $123.4 million.
-
Significant Reduction in Net Loss
The company reported a net loss of $14.4 million in Q2 2026, a substantial improvement from a $49.9 million net loss in Q2 2025. Year-to-date net loss also narrowed to $37.9 million from $93.8 million in the prior year.
-
Secured Long-Term Mitomycin Supply
UroGen Pharma entered into a 10-year supply agreement with TAPI NL B.V. for mitomycin, a critical active pharmaceutical ingredient for its commercial products, effective January 1, 2026. This new agreement enhances supply chain stability.
-
Increased Long-Term Debt for Refinancing and Working Capital
Long-term debt increased to $188.7 million as of June 30, 2026, from $122.2 million at year-end 2025. This includes a $75.0 million net additional borrowing from a Pharmakon loan refinancing in February 2026, with remaining proceeds for general corporate purposes and working capital.
Analysis · URGN · Life Sciences
UroGen Pharma reported robust Q2 2026 financial results, with revenue nearly tripling year-over-year, primarily driven by strong sales of its newly launched drug, Zusduri. This significant top-line growth led to a substantial reduction in net loss, indicating a clearer path towards profitability. The company also secured a critical 10-year supply agreement for mitomycin, a key active ingredient for its products, enhancing supply chain stability. While long-term debt increased due to refinancing, management asserts sufficient cash runway for over a year. This filing demonstrates strong commercial execution and improved financial health.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, URGN was trading at $41.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $15.86 to $43.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.